Program Introduction

Explore Hereditary Angioedema treatment, emphasizing individualized care, first-line therapeutic options and investigational agents in clinical development. 

Learning Objectives

• Analyze Hereditary Angioedema’s (HAE) pathophysiology to explain its underlying mechanisms.
• Evaluate the impact of HAE on affected individuals to appreciate the condition's severity and implications.
• Compare and contrast different therapeutic options available for HAE to determine their effectiveness.
• Investigate and predict developments in future therapies for HAE to understand the direction of medical research and potential innovations.

Available Credit

• 1.00 AMA PRA Category 1 Credit™
• 1.00 Participation

Program Introduction

Join Leo Wang and Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD), covering its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don’t miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.

Learning Objectives

• Evaluate the use of RWS as an outcome measure for FSHD clinical trials to measure disease progression, impact on ADLs, and effect of therapy
• Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

• 1.00 AMA PRA Category 1 Credit^TM
• 1.00 Participation

Program Introduction

This program brings together leading experts to explore advancements in the diagnosis and treatment of Alzheimer’s disease (AD). Presented by Marc E. Agronin, MD, R. Scott Turner, PhD, MD, and Susan Scanland, MSN, this program addresses key challenges and solutions in AD care. Topics include strategies for early detection and diagnosis through cognitive assessments, neuroimaging, and biomarker analysis; the role of novel and investigational disease-modifying therapies and the integration of therapeutic approaches, including FDA-approved treatments and nonpharmacologic interventions. The session emphasizes the importance of multidisciplinary management and shared decision-making with patients and caregivers to create comprehensive and effective care plans.

Learning Objectives

• Identify biomarkers in screening for Alzheimer’s disease and in continual assessment of symptoms
• Recognize the safety and efficacy of novel therapies that are approved as well as investigational therapies in late-stage development in Alzheimer’s disease
• Assess opportunities to screen for early-stage Alzheimer’s disease including various administration methods, cognitive assessments and imaging

Available Credit

• 1.0 AMA PRA Category 1 Credit™
• 1.0 Participation

Program Introduction

This educational activity, presented by Dr. Deligiannidis, Dr. Vega, and Dr. Smith, offers clinicians an essential update on perinatal depression (PND), including its pathophysiology, diagnosis, and treatment options. With a focus on the latest research and therapeutic advancements, this session highlights the significant impact of timely diagnosis and the risks of delayed intervention.

Participants will explore the neurobiological underpinnings of PND, including mechanisms such as altered GABAergic neurotransmission and the roles of neuroactive steroids like allopregnanolone. The presentation also reviews evidence-based approaches, covering both traditional antidepressants (SSRIs, SNRIs, TCAs) and innovative treatments like brexanolone and zuranolone. Practical insights on real-world applications, including considerations for the post-COVID era, provide clinicians with actionable knowledge to enhance care for patients affected by PND.

Learning Objectives

• Identify appropriate best practices for the diagnosis of PDP
• Implement evidence-based current therapies for patients with PDP

Available Credit

• 1.00 AMA PRA Category 1 Credit^TM
• 1.00 Participation